Protagonist Therapeutics, Inc (PTGX) Net margin 2017–2025
Protagonist Therapeutics, Inc (PTGX) net profit margin by fiscal year — reported net income divided by reported revenue.
-282.8%FY2025 · since FY2017: -184.2% → -282.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -282.8% | -346.2 pp |
| FY2024 | 63.3% | +194.9 pp |
| FY2023 | -131.6% | +347.7 pp |
| FY2022 | -479.3% | -20.3 pp |
| FY2021 | -458.9% | -227.9 pp |
| FY2020 | -231.1% | +33183.2 pp |
| FY2019 | -33414.3% | -33288.4 pp |
| FY2018 | -125.9% | +58.3 pp |
| FY2017 | -184.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX RevenuePTGX Net incomePTGX Gross profitPTGX Gross marginPTGX Operating incomePTGX Operating marginPTGX Operating cash flowPTGX Free cash flowPTGX Capital expendituresPTGX Return on equityPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Total liabilitiesPTGX Shareholders’ equityPTGX overview →